Esketamine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Esketamine

Examples of brand names: Ketanest S [DE]; Spravato [EU]

ATC code: N01AX14 (injection/anaesthesia); N06AX27 (nasal/antidepressant)

Main use (for orientation): Anaesthesia; depression, depending on formulation

Documented research summary

A mouse experiment explicitly investigated S-ketamine. CBD reduced excessive locomotor activity while preserving the antidepressant-like test effect. This does not support a clinical conclusion about combination with esketamine nasal spray.

Uncertainties and limitations

Preprints not peer reviewed; mixed arm not specific to esketamine; do not extrapolate animal doses/routes to nasal spray.

Research is limited to the specified date and protocol; it is not globally exhaustive. Brand names and authorisations do not constitute a complete current market overview.

Structured assessment

Category: Direct pair finding

Cannabinoid scope: 28 register names in the documented search family; neither 28 individual clinical trials nor a blanket assessment of all cannabinoids.

Evidence status: Pair-specific evidence, distinguished in the individual findings

Mechanism / drug context: CBD alters S-ketamine effects in mice; AMPA signalling investigated.

Type of supporting material: See the separate original findings

Clinical interpretation: Requires individual assessment by a doctor or pharmacist. Lack of evidence does not establish safety; no dosage or discontinuation advice is provided.

Context: Esketamine = S-ketamine, intranasal SPRAVATO as hydrochloride; active drug, not identical to racemic intravenous ketamine.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [CA_L_D0155]: Drug context

Statement supported: Supports dosage form, metabolism and/or known risks; alone, it does not substantiate a cannabinoid–drug pair finding.

Source: SPRAVATO (ESKETAMINE HYDROCHLORIDE) SOLUTION [JANSSEN PHARMACEUTICALS, INC.] [CA_L_D0155]

Source role [CA_P_34157363]: Pair finding

Statement supported: CBD reduced S-ketamine-induced hyperlocomotion while preserving the antidepressant-like test effect.

Source: Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects. [CA_P_34157363]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: The complete stored individual review, label review, literature screening, conclusion and uncertainties were read. Targeted sections of original information were rechecked; no claim is made that all product information or full texts were completely revalidated.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – laboratory and animal studies

Finding ID: V6_D0155_1

Type of result: Finding within the documented study context

Observation: CBD reduced S-ketamine-induced hyperlocomotion while preserving the antidepressant-like test effect.

Mechanism: Pharmacodynamics; AMPA signalling pathways investigated

Study type: Mouse experiment

Context studied: Sartim et al. 2021: S-ketamine in the methods section.

Clinical interpretation: Cannot be extrapolated to clinical nasal-spray safety.

Limitations and uncertainties: Animal behaviour is not human treatment success; no dosage recommendation.

Original sources for this finding: Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects. [CA_P_34157363]

References and access status

[CA_L_D0155] SPRAVATO (ESKETAMINE HYDROCHLORIDE) SOLUTION [JANSSEN PHARMACEUTICALS, INC.]

Original source / bibliographic reference

Authors: Janssen Pharmaceuticals, Inc.

Year: 2026

Source type: Current published human-use SPL / product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_34157363] Co-administration of cannabidiol and ketamine induces antidepressant-like effects devoid of hyperlocomotor side-effects.

Original source / bibliographic reference

Authors: Sartim AG, Marques J, Silveira KM, Gobira PH, Guimarães FS, Wegener G, Joca SR.

Year: 2021

Source type: Research Support, Non-U.S. Gov't; Journal Article

DOI: 10.1016/j.neuropharm.2021.108679

PMID: 34157363

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility